Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Beyondspring Inc BYSI

Healthcare Biotechnology
BeyondSpring Inc. is a clinical-stage global biopharmaceutical company. The Company is focused on developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs. The Company operates through two segments: the Plinabulin pipeline and Targeted Protein Degradation (TPD) platform. Plinabulin is being developed as a pipeline in a drug in various cancer... see more

Recent & Breaking News (NDAQ:BYSI)

BeyondSpring Initiates Expanded Access Program with Plinabulin for Patients Suffering from CIN in the U.S.

GlobeNewswire August 11, 2020

New Stem Cell-Based Application for BeyondSpring's Plinabulin Presented at ISSCR Annual Meeting

GlobeNewswire June 30, 2020

New Preclinical Data Demonstrates Immune-Enhancing Effects of Triple I/O Combination Therapy with BeyondSpring's Plinabulin

GlobeNewswire June 23, 2020

BeyondSpring Announces Pricing of Ordinary Shares

GlobeNewswire June 19, 2020

BeyondSpring Announces Proposed Public Offering of Ordinary Shares

GlobeNewswire June 18, 2020

BeyondSpring Announces Positive Topline Interim Results from PROTECTIVE-2 (Study 106) Phase 3 Trial Evaluating Superiority of Plinabulin in Combination with Neulasta for Chemotherapy-Induced Neutropenia Prevention

GlobeNewswire June 15, 2020

BeyondSpring Reports First-Quarter 2020 Financial Results and Operational Update

GlobeNewswire June 11, 2020

BeyondSpring's PROTECTIVE-2 (Study 106) Phase 2 Trial for Chemotherapy-Induced Neutropenia Shows Positive Results in Chemotherapy Optimization with Potentially Better Clinical Outcomes

GlobeNewswire June 9, 2020

BeyondSpring Announces Data & Safety Monitoring Board Recommendation for Plinabulin to Continue NSCLC Phase 3 Dublin-3 Study Without Modification

GlobeNewswire June 3, 2020

BeyondSpring E-Poster Presented at 2020 ASCO Virtual Scientific Program

GlobeNewswire June 2, 2020

BeyondSpring Granted New U.S. Patent for Plinabulin to Treat Severe Chemotherapy-Induced Neutropenia from Taxane in Cancer Patients

GlobeNewswire May 13, 2020

BeyondSpring Files 2019 Annual Report on Form 20-F

GlobeNewswire April 30, 2020

BeyondSpring Reports Fourth-Quarter and Full-Year 2019 Financial Results and Operational Update

GlobeNewswire April 30, 2020

CORRECTION - FDA Submission to Change the Primary Endpoint into an Industry First and Robust Clinical Measure for Superiority of CIN Phase 3 Study

GlobeNewswire April 29, 2020

FDA Submission to Change the Primary Endpoint into an Industry First and Robust Clinical Measure for Superiority of CIN Phase 3 Study

GlobeNewswire April 29, 2020

BeyondSpring to Host Fourth-Quarter and Full-Year 2019 Financial Results and Operational Update Conference Call on April 30, 2020

GlobeNewswire April 23, 2020

BeyondSpring Initiates New Drug Application Rolling Submission for Plinabulin in China for Chemotherapy-Induced Neutropenia

GlobeNewswire March 30, 2020

BeyondSpring's Plinabulin May Prevent Tissue Iron Overload in Anemic Cancer Patients Receiving Chronic Blood Transfusions During Chemotherapy

GlobeNewswire March 23, 2020

BeyondSpring Files for Patent Protection on BPI-002 for the Treatment of Viral Infections Including COVID-19

GlobeNewswire March 11, 2020

BeyondSpring's Plinabulin Stimulates Both the Adaptive and Innate Immune System in Cancer Patients

GlobeNewswire February 10, 2020